TTM
−$117.53M
YoY change
-23.6%
5Y CAGR
—
Peak year (2019)
−$15.16M
Cumulative operating income
−$656.45M
Operating Income history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: −$111.29M
Operating Income growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -23.6%
Operating Income history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | −$111.29M | -23.6% | +$34.31M | ||
| 2024 | −$145.59M | +27.5% | −$31.42M | ||
| 2023 | −$114.17M | +2.8% | −$3.10M | ||
| 2022 | −$111.07M | +90.9% | −$52.88M | ||
| 2021 | −$58.19M | +11.5% | −$5.99M | ||
| 2020 | −$52.20M | +244.3% | −$37.04M | ||
| 2019 | −$15.16M | — | — |
- 2025−$111.29M-23.6%
- 2024−$145.59M+27.5%
- 2023−$114.17M+2.8%
- 2022−$111.07M+90.9%
- 2021−$58.19M+11.5%
- 2020−$52.20M+244.3%
- 2019−$15.16M—
Operating Income values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's current operating income (TTM) is −$117.53M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Tango Therapeutics (TNGX) operating income is −$111.29M – declined 23.6% year-over-year.
2019 marks the peak operating income at −$15.16M, with the historical low of −$145.59M recorded in 2024.
Tango Therapeutics Operating Income by Year
Tango Therapeutics Operating Income 2025: −$111.29M
Tango Therapeutics posted operating income of −$111.29M in 2025, declined 23.6% below 2024.
Tango Therapeutics Operating Income 2024: −$145.59M
In 2024, Tango Therapeutics reported operating income of −$145.59M, grew 27.5% from 2023. This figure represents the lowest annual value in the available history.
Tango Therapeutics Operating Income 2023: −$114.17M
Tango Therapeutics operating income in 2023 was −$114.17M, edged up 2.8% from 2022.
Tango Therapeutics Operating Income 2022: −$111.07M
2022's operating income for Tango Therapeutics came in at −$111.07M, surged 90.9% from 2021.
Tango Therapeutics Operating Income 2021: −$58.19M
Tango Therapeutics operating income in 2021 was −$58.19M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Operating Income
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation